Syncromune™
Charles Link has an extensive work experience in the pharmaceutical and biotechnology industry. Charles is the founder, president, and chief medical officer of Syncromune since December 2020. In addition, they are the founder and chairman of ChainLink Pharma since January 2021. Charles also serves as a board member of Viewpoint Molecular Targeting, Inc. since March 2021 and as a member of the board of directors of QSAM Biosciences, Inc. since February 2021. Previously, they founded and served as the CEO of BioProtection Systems Corporation from January 2010 to August 2019. Prior to that, Charles was the founder, chairman, and CEO of NewLink Genetics from July 1999 to August 2019.
Charles Link's education history includes attending Stanford University School of Medicine, where they did not specify a start or end year or a degree or field of study. Charles also participated in the Medical Oncology Residency Program at the National Cancer Institute (NCI) with no given dates or degree name. Charles earned a Bachelor's degree from Stanford University, and finally, they pursued Chemistry at the United States Air Force Academy, again without specified dates or a degree.
This person is not in any teams
This person is not in any offices
Syncromune™
1 followers
Syncromune™ is a privately held, clinical stage biopharmaceutical company dedicated to the development of better immunotherapies for metastatic solid tumor cancers. We are at the forefront of developing combination immunotherapies, which several thought leaders consider to be the future of cancer therapy. We are committed to bringinglife-changing treatments to patients with unmet medical needs by fighting cancer in a new way. The company is currently developing Syncrovax™, a proprietary platform technology that uses a combination approach to synchronize the timing and location of tumor antigen release with the functional activation and education of immune cells. An in situ vaccine is created from the patient’s own tumor antigens, making it a personalized treatment for each patient. The platform is designed to optimize T cells and the immune system to treat metastatic solid tumors where other therapies have failed.